Trials / Completed
CompletedNCT00150462
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's macroglobulinemia. Carfilzomib is a proteasome inhibitor, an enzyme responsible for degrading a wide variety of cellular proteins.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carfilzomib | Administered as an IV bolus dose |
| DRUG | Dexamethasone | Administered orally prior to carfilzomib |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2005-09-08
- Last updated
- 2017-05-02
- Results posted
- 2015-12-03
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00150462. Inclusion in this directory is not an endorsement.